fbpx
Monday, March 1, 2021
No menu items!

Eli Lilly’s antibody combination receives FDA emergency use authorization for COVID-19

The U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Eli Lilly’s combination antibody therapy to fight COVID-19, the U.S. drugmaker said on Tuesday (February 9).

Eli Lilly’s combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%, data from a late-stage trial showed in January.

“This therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization”, the company said in a statement.

(Production: Kia Johnson)

Advertisement

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News

California provides $6.6 billion to reopen schools

California's governor said on Monday (March 1) he and Democratic lawmakers had reached a deal to fund...

Security barriers near White House are removed after almost nine months

The fencing that separated Black Lives Matter Plaza from the park outside the White House was removed by workers on Monday (March...

S&P 500 surges in strongest one-day rise since June

The S&P 500 surged on Monday (March 1) in its strongest one-day gain since June as bond markets calmed after a month-long...

Suspect Arrested in Fatal Shooting

Charges have been upgraded against a suspect arrested in the fatal shooting of a man at 233 Rosamond Street that occurred about...

Myanmar killings are an escalation, further action being readied -White House

Recent killings of protesters in Myanmar represent an escalation of the situation there, White House press secretary Jen Psaki said on Monday...

More Articles Like This